Biogen and Eisai said the European Medicines Agency's Committee for Medicinal Products for Human Use has reaffirmed its recommended approval of their Alzheimer's drug Leqembi.
The European Union's drugs regulator said on Friday it concluded a review into the safety of Eisai and Biogen's Alzheimer's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback